Physician profile
Keyur Parikh
NPI 1700157450
$89,198.85
in general payments reported to CMS, 2019-2025
38 companies · $47K in 2025
The $47K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $95.24 · 2021: $335 · 2022: $1,319 · 2023: $14K · 2024: $25K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $73K · Travel and Lodging: $9,066 · Food and Beverage: $4,558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $73,312.50 |
| Travel and Lodging | $9,065.71 |
| Food and Beverage | $4,557.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $86,114.32 | 2019-2025 | |
| Pfizer INC. | $449.82 | 2019-2025 | |
| Apollo Endosurgery US INC | $294.99 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $272.78 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $232.72 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $195.40 | 2019-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $182.29 | 2024-2025 | Voquezna |
| Vivus LLC | $159.18 | 2019-2025 | Qsymia |
| Gilead Sciences, INC. | $150.22 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $139.73 | 2020-2024 | Dificid |
| Qol Medical, LLC | $119.29 | 2022-2025 | Sucraid |
| Braintree Laboratories, INC. | $100.34 | 2021-2022 | |
| Lilly USA, LLC | $77.29 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $64.90 | 2024-2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $59.29 | 2024 | Iqirvo, Bylvay |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $52.77 | 2019-2025 | Wegovy |
| Aimmune Therapeutics, INC. | $50.91 | 2023-2024 | |
| Genzyme Corporation | $47.39 | 2023-2024 | |
| Intercept Pharmaceuticals, INC. | $39.19 | 2022-2024 | |
| Ferring Pharmaceuticals INC. | $37.33 | 2023-2025 | Rebyota |
| Ardelyx, INC. | $35.98 | 2022-2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $33.76 | 2023-2024 | Dupixent |
| Fresenius Kabi USA, LLC | $31.94 | 2023-2024 | Idacio |
| Evoke Pharma, INC. | $30.44 | 2022-2025 | |
| Shionogi INC | $30.07 | 2019 | |
| Madrigal Pharmaceuticals | $27.04 | 2025 | Rezdiffra |
| Celgene Corporation | $25.85 | 2022 | |
| Shire North American Group INC | $24.76 | 2019 | |
| Romark Laboratories, Lc | $18.86 | 2019 | |
| Organon LLC | $18.00 | 2024 | |
| Stryker Corporation | $17.99 | 2025 | Neptune |
| Medtronic, INC. | $16.86 | 2024 | Gi Genius |
| Nestle Healthcare Nutrition INC. | $16.83 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.67 | 2023 | Cyltezo |
| Boston Scientific Corporation | $13.65 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keyur Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.